Journal of Oncology Pharmacy Practice最新文献

{"title":"Enhancing medication adherence with blister-packed oral oncolytics: A case example in chronic lymphocytic leukemia.","authors":"Eric P Borrelli, Nathan Barnes, Heather Nelkin, Peter Saad, Doina Dumitru, Julia D Lucaci","doi":"10.1177/10781552241306704","DOIUrl":"https://doi.org/10.1177/10781552241306704","url":null,"abstract":"<p><strong>Introduction: </strong>Medication nonadherence is a prevalent issue in the oncology population and can be costly on the healthcare system while leading to worsened outcomes, including increased mortality. One intervention that has been shown to help promote medication adherence to oral therapies for chronic conditions is blister-packaging. However, no literature is available assessing the potential impact of blister-packaging in oncology. Therefore, we aimed to quantify the impact of blister-packaging oral oncolytics on medication adherence and healthcare costs.</p><p><strong>Methods: </strong>An economic model was designed to assess the potential impact of blister-packaging oral oncolytics for chronic lymphocytic leukemia (CLL) patients in the U.S. The model took the perspective of the U.S. healthcare system and assessed newly diagnosed CLL cases initiating therapy, utilizing a one-year time horizon. The intervention of interest was blister-packaging oral therapies in the treatment of CLL, while the model evaluated the impact of this intervention on healthcare costs through improved patient adherence based on peer-reviewed literature.</p><p><strong>Results: </strong>This analysis consisted of 20,700 newly diagnosed patients with CLL initiating therapy. Initiating blister-packed oral therapies saw adherence increase by 1004 patients from 12,979 patients (62.7%) to 13,983 patients (67.5%). While an increase in pharmacy costs by $61,589,670 (+$247.95 per-patient per-month (PPPM)) was seen for the population, medical costs decreased by $82,285,847 (-$331.26 PPPM). Overall, this led to a net reduction in total healthcare costs of $20,696,177 (-$83.32 PPPM).</p><p><strong>Conclusions: </strong>Blister-packaging oral oncology drugs in CLL has the potential to reduce total healthcare expenditures by increasing medication adherence. Future studies are needed to evaluate the direct effects of blister-packaging oral oncolytics on clinical, healthcare resource utilization, and financial outcomes.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552241306704"},"PeriodicalIF":1.0,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143448313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Practical use of nadofaragene firadenovec-vncg for pharmacists.","authors":"Seth D Holler, Sara Moran Smith","doi":"10.1177/10781552251315146","DOIUrl":"10.1177/10781552251315146","url":null,"abstract":"<p><p>ObjectiveTo provide a practical approach to pharmacists regarding the safe and effective use of nadofaragene firadenovec.Data sourcesClinical study data and pharmacist experience in institutional settings.Data summaryThis review article discusses the role of pharmacists caring for patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) receiving nadofaragene firadenovec. Pharmacist roles in a multidisciplinary care team are described and involve considerations surrounding nadofaragene firadenovec, including its mechanism of action, indication, handling, storage, administration, adverse event profile, disposal, counseling, and other practical points.ConclusionsPharmacists are positioned to be key contributors to the care team regarding the effective use of nadofaragene firadenovec. Further awareness and education will continue to optimize the clinical use of nadofaragene firadenovec in the high-risk BCG-unresponsive NMIBC setting.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251315146"},"PeriodicalIF":1.0,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143441201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Daratumumab desensitization: Novel approaches in POEMS syndrome experience.","authors":"Rosalaura Villarreal-González, Nataly Flores-García, Diana Cadenas-García, Andrés Gómez-De León, Rafael Piñeiro-Retif, Oscar Vidal-Gutiérrez","doi":"10.1177/10781552251316477","DOIUrl":"https://doi.org/10.1177/10781552251316477","url":null,"abstract":"<p><p>Daratumumab is a human IgG1κ monoclonal antibody targeting CD38, with infusion-related reactions occurring in 45-48% of patients. Among these, 5-10% are severe, requiring treatment discontinuation in 1% of cases. The incidence of hypersensitivity reactions (HSRs) to daratumumab is unknown. We describe a 37-year-old male diagnosed with POEMS syndrome and treated with autologous hematopoietic stem cell transplantation and chemotherapy. Presenting a relapse of the disease, intravenous daratumumab was initiated. Ten minutes after starting the first infusion, he presented with generalized rash, abdominal pain, vomiting, pharyngeal pruritus, throat tightness, dyspnea, decreased oxygen saturation, tachycardia and diaphoresis (Brown III). Due to the refractory disease and lack of alternatives, a desensitization protocol for daratumumab 1000 mg was implemented using a (3 bag-12 step) over 5.67 h. Eight successful desensitizations were performed without hypersensitivity reactions, enabling safe drug reintroduction. Currently, only one successful daratumumab desensitization protocol has been published, involving a 4-bag, 14-step procedure over 5.2 h, as reported by Carrón-Herrero et al. Prior to desensitization, the patient experienced flushing, pharyngeal pruritus, bronchospasm, dyspnea, desaturation, bradycardia, and hypotension. Both case reports were associated with severe anaphylaxis, ultimately enabling the safe reintroduction of the drug.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251316477"},"PeriodicalIF":1.0,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143441189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of first and third generation EGFR-TKIs for the treatment of advanced non-small cell lung cancer: A real-world study.","authors":"Maitri Shah, Kashvi Shah, Hetvi Dave, Avinash Khadela, Chirag Desai, Sanket Shah, Gaurang Shah","doi":"10.1177/10781552251320349","DOIUrl":"https://doi.org/10.1177/10781552251320349","url":null,"abstract":"<p><strong>Background: </strong>Worldwide, lung cancer stands as a leading cause of mortality, with EGFR-mutated metastatic non-small cell lung cancer (NSCLC) accounting for a large percentage of cases in the Indian population. Different generations of EGFR-tyrosine kinase inhibitors (TKIs) are available to treat EGFR-mutated NSCLC. The purpose of our research was to evaluate and compare the superiority of osimertinib over gefitinib/erlotinib in terms of clinical effectiveness and safety.</p><p><strong>Methods: </strong>A retrospective observational cohort study was conducted at the Clinical Oncology Center in the Western region of India. Patients suffering from EGFR-mutated metastatic NSCLC were recruited for the study. The response of EGFR-TKIs was assessed using objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and incidence of adverse events (AE).</p><p><strong>Results: </strong>A total of 75 patients treated with EGFR TKIs were enrolled in the study. The ORR of osimertinib and gefitinib/erlotinib was 11.11% and 25.64% (p = 0.142) and DCR was found to be 69.44% and 82.05% (p = 0.28) respectively. Osimertinib and gefitinib/erlotinib had respective median PFS of 8.43 and 10.68 months. The incidence of AE of osimertinib and gefitinib/erlotinib was 1.94 and 2.49 respectively.</p><p><strong>Conclusion: </strong>Osimertinib was not found to be superior over gefitinib/erlotinib based on clinical effectiveness. Though it showed a better safety profile, the cost of the treatment of osimertinib over gefitinib/erlotinib was not justifiable.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251320349"},"PeriodicalIF":1.0,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143441186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of BRCA 1 mutated breast cancer with a PARP inhibitor and an Immune Checkpoint Inhibitor.","authors":"Christina Hoppe, Kiera Roubal, Sushma Pavuluri, Oleksandra Lupak","doi":"10.1177/10781552251320049","DOIUrl":"https://doi.org/10.1177/10781552251320049","url":null,"abstract":"<p><strong>Introduction: </strong>Triple negative breast cancer (TNBC) has traditionally been challenging to treat due to its lack of hormone receptors (HR) and human epidermal growth factor receptor 2 (HER2), which were perceived as the only \"targets\" for treatment of breast cancer. Since 2017, targeted treatment options, such as olaparib, have been approved for the treatment of germline BReast CAncer gene (BRCA) mutated breast cancer, and immune checkpoint inhibitors for TNBC.</p><p><strong>Case report: </strong>A 45-year-old female was diagnosed with BRCA1 mutated TNBC and ovarian cancer in 2018, and adjuvant treatment was partially completed. In 2020, her CA-125 rose and olaparib was initiated. Due to tolerability, she stopped treatment and transitioned to surveillance. In 2021, imaging showed brain metastases, and she started capecitabine. In November 2021 she progressed and transferred care to us.</p><p><strong>Management and outcome: </strong>Due to suspected dual metastatic TNBC and ovarian cancers, and ovarian tissue demonstrating a combined positive score (CPS) of 3, gemcitabine, carboplatin and pembrolizumab were initiated. After six cycles, imaging demonstrated resolution of brain lesions, and pembrolizumab maintenance was continued. In March 2023, she switched to carboplatin, paclitaxel and bevacizumab, due to suspected progression of her ovarian cancer and resolution of breast cancer. She continued until December 2023 and switched to olaparib and bevacizumab.</p><p><strong>Discussion: </strong>There is limited data to support sequential use of immunotherapy following treatment with a poly (ADP-ribose) polymerase (PARP) inhibitor. The case report presented here demonstrates successful treatment of a patient with BRCA1 mutated TNBC treated with pembrolizumab after olaparib.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251320049"},"PeriodicalIF":1.0,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143441215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Initial real-world experience with ribociclib in advanced breast cancer.","authors":"Azhar Nawaz, Jamal Zekri, Haleem Rasool, Refaei Ibrahim","doi":"10.1177/10781552251317962","DOIUrl":"https://doi.org/10.1177/10781552251317962","url":null,"abstract":"<p><strong>Purpose: </strong>CDK4/6 inhibitors, such as ribociclib, are recommended in combination with hormonal therapy to treat advanced/metastatic hormone receptor-positive, HER2-negative breast cancer. The objectives of this study are to evaluate the therapeutic outcome and tolerance of ribociclib in patients treated at our institution.</p><p><strong>Methods: </strong>The initial cohort of patients who received >1 cycle of ribociclib between December 2018 and March 2022 were included. Rates of adverse events (AEs) related dose reduction and discontinuation of ribociclib were used as a surrogate marker for intolerance.</p><p><strong>Results: </strong>Sixty-eight female patients were included. Ribociclib was administered with letrozole or fulvestrant in the first-, second-, third-, and fourth-line palliative hormonal therapy settings in 29 (42.6%), 26 (38.2%), 12 (17.6%) and 1 (1.5%) patients respectively. Adverse events (AEs) related dose reduction was reported in 30 (44%) patients. Ribociclib was permanently discontinued in 42/68 (61.8%) patients [Disease progression 33/68 (48.5%) and AEs 9 (13.2%)]. Objective response was documented in 10/61 (16.4%) evaluable patients. The median progression free survival (PFS) was 18 months (95% CI: 11.7-24.3). The median overall survival (OS) was not reached and 84% of patients were alive at 3 years.</p><p><strong>Conclusions: </strong>Although objective response rates were modest in this mixed cohort of heavily pretreated patients, ribociclib combined with letrozole or fulvestrant has shown robust PFS and OS in real-world practice. AEs related treatment discontinuation rate is higher than that reported in clinical trials with stringent inclusion criteria.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251317962"},"PeriodicalIF":1.0,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143441199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management and desensitization to Avelumab in anaphylaxis and metastatic urothelial carcinoma: A case report.","authors":"Rosalaura Villarreal-González, Ana Karen Treviño-Morales, Diana Cadenas-García, Ángel López-Galindo, Oscar Vidal-Gutiérrez","doi":"10.1177/10781552241313057","DOIUrl":"https://doi.org/10.1177/10781552241313057","url":null,"abstract":"<p><strong>Introduction: </strong>Urothelial carcinoma is the prevailing type of bladder cancer, characterized by expression of the programed death-ligand-1-protein (PD-L1). Avelumab is an anti-PD-L1 monoclonal antibody used in urothelial carcinoma. It is associated with an incidence of 47.4% and 25.2% in grade 3 adverse events or greater, respectively; gastrointestinal symptoms and cutaneous affections are the most common.</p><p><strong>Case report: </strong>A 52-year-old male with a history of rectal cancer and non-muscle-invasive bladder carcinoma. PET/CT revealed adenopathies in the pelvic region, the biopsy confirmed metastatic urothelial carcinoma. Next PET/CT indicated progression. Treatment with Cisplatin + Gemcitabine led to complete response after 4 cycles. Maintenance with Avelumab was indicated. Fifteen minutes after the first Avelumab administration, the patient experienced hypotension, presyncope, skin itching, and nasal congestion. Epinephrine, hydrocortisone, and physiological solution were administered, with resolution of symptoms.</p><p><strong>Management & outcome: </strong>Since Avelumab is first-line maintenance therapy in this patient, a desensitization protocol was performed with (3-bag, 12-steps). The patient was premedicated with acetaminophen and chlorpheniramine. The protocol was successfully completed without hypersensitivity reactions for 6 cycles.</p><p><strong>Discussion: </strong>Patients with hypersensitivity reactions to their first line of treatment are challenged to continue the best approach. We detail the case of a patient diagnosed with metastatic urothelial carcinoma who underwent a desensitization protocol for Avelumab after presenting a severe allergic reaction. The patient tolerated Avelumab throughout the protocol with no complications, achieving the total dosage for his maintenance therapy; drug desensitization is a safe and effective procedure in patients with hypersensitivity reactions to their first-line treatment.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552241313057"},"PeriodicalIF":1.0,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"End-of-life symptoms and polypharmacy in lung and other cancer patients receiving palliative care in Turkey.","authors":"Vildan Kocatepe, Halide Fulya Uludağ Kızıltepe, Dilek Yildirim, Özlem Oruç","doi":"10.1177/10781552251316180","DOIUrl":"https://doi.org/10.1177/10781552251316180","url":null,"abstract":"<p><strong>Introduction: </strong>Patients diagnosed with cancer are often prescribed a wide range of medicines. In this study, it was aimed at examining the end-of-life symptoms and polypharmacy status of patients hospitalized in the palliative care unit with the diagnosis of lung cancer and other cancers.</p><p><strong>Methods: </strong>The data for the retrospective-descriptive study were obtained from hospital records and an automation system. The sample of the study included the data of all patients (n = 201) who were hospitalized in the palliative care unit between 2016-2021 in Turkey.</p><p><strong>Results: </strong>The most common symptoms of end-of-life patients were dyspnea (85.1%) and pain (67.7%). The mean number of medications used by the patients on the day of death was 10.89 ± 3.16, it was 12.50 ± 3.11 on the third day before death, 13.24 ± 3.07 on the 6th day before death, 13.50 ± 3.03 on the 9th day before death. There was a statistically significant difference between the mean number of medications used by the patients according to the presence of dyspnea on the day of death (t = 1.997; p = .047) and pain on the day of death (t = 3.781; p = .001). There was a statistically significant difference between the mean number of medications used by the patients according to the presence of pain on the sixth day before death (t = 2.613; p = .010) and the ninth day before death (t = 2.940; p = .004).</p><p><strong>Conclusion: </strong>The number of medications used by the patients decreased from the 9th day before death to the day of death and their polypharmacy status continued.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251316180"},"PeriodicalIF":1.0,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Descriptive analysis of the efficacity of R-GEMOX /R-IE/R-CEPP in patients with relapsed/refractory (R/R) transplant-ineligible diffuse large B-cell lymphoma (DLBCL).","authors":"Baptiste Fulbert, Théo Vincent, Justine Clarenne, Imman Abdelouahab, Antoine Le Bozec, Eric Durot, Florian Slimano","doi":"10.1177/10781552241313381","DOIUrl":"https://doi.org/10.1177/10781552241313381","url":null,"abstract":"<p><strong>Background: </strong>Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) ineligible for Hematopoietic Stem Cell Transplantation (HSCT) may benefit from a second line anticancer drug regimen but real-life outcomes are lacking.</p><p><strong>Objective: </strong>To describe the efficacity of 3 anticancer drug regimens (Gemcitabine and Oxaliplatin GEMOX; Ifosfamide and Etoposide IE; Cyclophosphamide, Etoposide, Procarbazine and Prednisone CEPP) combined with Rituximab (R-) in terms of progression-free (PFS) and overall survival (OS).</p><p><strong>Patients: </strong>Retrospective study including R/R DLBCL patients HSCT ineligible who received at least one cycle of R-GEMOX, R-IE or R-CEPP between 2010 and 2022. Demographic, clinical, biological and survival data were collected. Univariate and multivariate analysis were performed to identify associated variables with survival outcomes.</p><p><strong>Results: </strong>Sixty-two patients (median age 78 [40-102] with predominantly stage III-IV DLBCL (n = 49, 79%), non-germinal center-B like (n = 27, 44%) were included. Median OS and PFS were 9 (CI95% [3-10]) and 4 months (CI95% [2-13]) for R-GEMOX, 4 (CI95% [2-6]) and 1 month (CI95% [1-4]) for R-IE and 5 (CI95% [3-6]) and 3 months (CI95% [2-15]) for R-CEPP, respectively. Univariate analysis selects ECOG, aa-IPI scores, LDH rate and Ann-Arbor stage with no independently association in multivariate analysis.</p><p><strong>Conclusion: </strong>All three regimens show modest survival benefit especially between last anticancer treatment course and death. Emergence of bispecific antibodies and Cart-cells for which real-life benefits have yet to be demonstrated could be coupled with improved access to early palliative care.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552241313381"},"PeriodicalIF":1.0,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacotherapy and psychological support: Integrating pharmacists into comprehensive cancer care - a literature review.","authors":"Haneen Badreldin Ali, Ujunwa P Dike, Muhammad Burhan Khan, Naiba Khusrau","doi":"10.1177/10781552251316827","DOIUrl":"https://doi.org/10.1177/10781552251316827","url":null,"abstract":"<p><p>Cancer presents significant physical and mental challenges to patients. Therefore, psychological assessment is important following a cancer diagnosis, as well as during and after chemotherapy. In cancer treatment, the goal of healthcare providers, including pharmacists, should be to deliver holistic care that addresses important aspects of patients' health, with particular emphasis on their psychological readiness to combat their diseases. This article reviews published literature from Google Scholar and PubMed to examine the relevant pharmacotherapy and psychotherapy approaches to managing psychological issues in cancer patients. This article also discusses how pharmacists can be integrated into cancer patients' mental health care, while highlighting the potential benefits and challenges associated with this approach. We conclude that the integration of pharmacists into psychological care and support for cancer patients holds promise due to their knowledge of cancer chemotherapy, their ability to improve their knowledge about psychological care, and their capacity to collaborate with other healthcare professionals in cancer treatment.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251316827"},"PeriodicalIF":1.0,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}